Objective: To survey patients' experiences with the switch from an originator biologic to a biosimilar growth hormone.
Design: Questionnaire.
Method: We developed a questionnaire in which patients were asked about their experiences with the switch from an originator biologic to a biosimilar growth hormone. The questionnaire was distributed to all 207 patients who were switched to the biosimilar in the Radboudumc since April 2014. The following topics were covered: (a) difficulties experienced in switching from originator to biosimilar; (b) patient education; (c) effectiveness of the biosimilar product; (d) possible adverse effects experienced; and (e) experience with application of the new injection system for the biosimilar.
Results: The questionnaire was completed by 79 patients (38.1%). Seventy-two percent of the patients indicated that before switching they had no concerns about switching. The other patients did have concerns beforehand, which were related to the different injection system (n=13), possible new adverse effects (n=13) and safety of the biosimilar (n=11). Before the switch was made, all patients had been informed in writing and also individually by endocrinologists and specialised nurses; 93% of the patients was satisfied with the counselling provided by Radboudumc. Concerning use of the new injection system, 95% of the patients indicated that they had received individual training and 98% was confident in using it. Patients rated the process of transition to the biosimilar at the Radboudumc an average of 7.8 (range: 1-10).
Conclusion: Patients were satisfied with the switch to the biosimilar growth hormone and there were few side-effects. Some minor problems were encountered, but these could be solved. Extensive counselling of patients before switching to prescription of biosimilars proved to be worthwhile. The switch has led to a significant reduction in costs.